STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2018

Dec 19, 2018

December 19, 2018

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza , Bandra‐Kurla Complex Bandra (E) Mumbai ‐ 400 051

Scrip code: STAR

Dear Sirs,

Strides and Mylan to release General Claims Escrow on Agila transaction

Strides to receive ~US$ 42 Mn immediately from General Claims Escrow

As announced on December 05, 2013, the Company and its wholly owned subsidiary, Strides Pharma Asia Pte Ltd (“Subsidiary”) completed the sale to Mylan Laboratories Limited and Mylan Institutional Inc. of Agila Specialties Private Limited and Agila Specialties Global Pte Limited respectively, pursuant to Sale and Purchase Agreements effective as of February 27, 2013 (“SPAs”) on December 04, 2013.

Mylan made claims against the General Claims Escrow which included a third‐party claim that was subject to resolution under international arbitration. The claims in that arbitration were rejected in their entirety. Strides will receive ~ US$ 42 Mn towards full and final release of the General Claims Escrow immediately.

You are requested to take the same on record.

For Strides Pharma Science Limited

==> picture [150 x 58] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [96 x 86] intentionally omitted <==

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com